

1 **Phage anti-CRISPR control by an RNA- and DNA-binding helix–turn–helix protein**

2
3 Nils Birkholz¹⁻⁴, Kotaro Kamata^{1,2}, Maximilian Feußner⁵, Max E Wilkinson⁶⁻¹⁰, Christian Cuba
4 Samaniego¹¹, Angela Migur¹², Dari Kimanius^{13,14}, Marijn Ceelen^{1#}, Sam C Went¹⁵, Ben
5 Usher¹⁵, Tim R Blower¹⁵, Chris M Brown¹⁶, Chase L Beisel^{12,17}, Zasha Weinberg⁵, Robert D
6 Fagerlund¹⁻⁴, Simon A Jackson¹⁻⁴ and Peter C Fineran^{1-4,*}

7
8 ¹Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand

9 ²Bioprotection Aotearoa, University of Otago, Dunedin, New Zealand

10 ³Genetics Otago, University of Otago, Dunedin, New Zealand

11 ⁴Maurice Wilkins Centre for Molecular Biodiscovery, University of Otago, Dunedin, New
12 Zealand

13 ⁵Bioinformatics Group, Department of Computer Science and Interdisciplinary Centre for
14 Bioinformatics, Leipzig University, Härtelstraße 16-18, 04107 Leipzig, Germany

15 ⁶Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA
16 02139, USA

17 ⁷Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

18 ⁸McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge,
19 MA 02139, USA

20 ⁹Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology,
21 Cambridge, MA 02139, USA

22 ¹⁰Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge,
23 MA 02139, USA

24 ¹¹Computational Biology Department, Carnegie Mellon University, Pittsburgh, PA 15213,
25 USA

26 ¹²Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz Centre for
27 Infection Research (HZI), Würzburg, Germany

28 ¹³MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK

29 ¹⁴CZ Imaging Institute, 3400 Bridge Parkway, Redwood City, CA 94065, USA

30 ¹⁵Department of Biosciences, Durham University, Stockton Road, Durham DH1 3LE, UK

31 ¹⁶Department of Biochemistry, University of Otago, Dunedin, New Zealand

32 ¹⁷Medical Faculty, University of Würzburg, Würzburg, Germany

33
34 #Present address: Institute for Integrative Biology, Department of Environmental Systems
35 Science, ETH Zürich, 8092 Zurich, Switzerland

36
37 * To whom correspondence should be addressed: peter.fineran@otago.ac.nz

38 SUMMARY

39

40 **In all organisms, regulation of gene expression must be adjusted to meet cellular**
41 **requirements and frequently involves helix–turn–helix (HTH) domain proteins¹. For**
42 **instance, in the arms race between bacteria and bacteriophages, rapid expression of**
43 **phage anti-CRISPR (*acr*) genes upon infection enables evasion from CRISPR–Cas**
44 **defence; transcription is then repressed by an HTH-domain-containing anti-CRISPR-**
45 **associated (Aca) protein, likely to reduce fitness costs from excessive expression²⁻⁵.**
46 **However, how a single HTH regulator adjusts anti-CRISPR production to cope with**
47 **increasing phage genome copies and accumulating *acr* mRNAs is unknown. Here, we**
48 **show that the HTH domain of the regulator Aca2 not only serves to repress Acr synthesis**
49 **transcriptionally through DNA binding, but also inhibits translation of mRNAs by**
50 **binding conserved RNA stem-loops and blocking ribosome access. The cryogenic electron**
51 **microscopy structure of the ~40 kDa Aca2–RNA complex demonstrates how the versatile**
52 **HTH domain specifically discriminates RNA from DNA binding sites. These combined**
53 **regulatory modes are widespread in the Aca2 family and facilitate CRISPR–Cas**
54 **inhibition in the face of rapid phage DNA replication without toxic *acr* overexpression.**
55 **Given the ubiquity of HTH-domain proteins, it is anticipated that many more elicit**
56 **regulatory control by dual DNA and RNA binding.**

57

58 MAIN TEXT

59

60 From the early days of molecular biology, it was recognized that gene expression must be
61 regulated to adjust the availability of gene products to the needs of the cell⁶. One major protein
62 motif that facilitates binding to DNA for activation or repression of gene transcription is the
63 helix–turn–helix (HTH) fold¹. The C-terminal “recognition” helix of this motif inserts into the
64 major groove of DNA and is connected by a sharp turn to the preceding helix, which stabilizes
65 the interaction. Many variations of this fold have been described (reviewed in ¹). Proteins with
66 HTH motifs, now known to be key players in various processes in higher organisms⁷⁻¹⁰, were
67 originally discovered in bacteria¹¹ and their viruses (called bacteriophages or phages)¹², where
68 novel roles continue to be explored. For example, in an ongoing arms race, bacteria use
69 CRISPR–Cas adaptive defence systems for protection against phages¹³, and phages in turn
70 deploy diverse anti-CRISPR (Acr) proteins as inhibitors¹⁴. Acr production is regulated by
71 phages through HTH-domain-containing anti-CRISPR-associated (Aca) proteins²⁻⁵. Acr and
72 Aca proteins are co-encoded in *acr–aca* operons^{14,15} whose transcription is auto-repressed
73 through binding of Aca dimers to inverted repeats in the promoter^{2-5,16-18} – presumably to
74 prevent fitness costs arising from expression of the *acr–aca* operon as it is transcribed from a
75 strong promoter early during phage infection^{3,19}. Aca-mediated control is likely important in
76 coordinating Acr dynamics: the Acr has to effectively inhibit CRISPR–Cas, but its synthesis
77 from accumulated mRNAs must then be suppressed. Importantly, this repression must be
78 maintained in the face of rapid phage DNA replication and the concomitant increase in *acr–*
79 *aca* operon copies to prevent fitness costs to the host cell, whose resources the phage depends
80 on to produce its virion components. However, how this complex task is accomplished by a
81 single, compact protein with a simple HTH fold is unclear.

82

83 **Aca2 is required for phage ZF40 fitness**

84 To investigate Acr regulation by an Aca HTH protein, we examined phage ZF40, which infects
85 *Pectobacterium carotovorum*²⁰ and contains an *acrIF8–aca2* operon^{2,15}. AcrIF8 inhibits the
86 type I-F CRISPR–Cas complex by blocking its ability to recognise target DNA²¹. We first
87 assessed the importance of Aca2 for phage ZF40 fitness. To this end, we established a phage
88 engineering method using homologous recombination and programming of an endogenous
89 type I-E CRISPR–Cas system to positively select mutant phages (**Extended data figure 1A**).
90 However, while cloning constructs using *Escherichia coli* that contained *acrIF8* but lacked
91 *aca2*, we only recovered empty vectors or plasmids with *acrIF8* mutations, suggesting that
92 *acrIF8* overexpression is toxic and that Aca2 limits toxicity. In agreement, cloning into *E. coli*
93 with *in-trans* complementation of *aca2* from a helper plasmid enabled successful construction
94 of *acrIF8* plasmids lacking *aca2*. To investigate whether unregulated *acrIF8* was toxic in the
95 native host *P. carotovorum*, we assessed how efficiently these cells were able to take up the
96 *acrIF8* plasmids by conjugation (**Figure 1A**). As donors, we used *E. coli* expressing *aca2 in*
97 *trans* and mobilizable plasmids with different *acrIF8–aca2* locus variants. These locus variant
98 plasmids were conjugated into *P. carotovorum* containing the Aca2 helper plasmid or the
99 corresponding empty vector. Whereas the wild-type (WT) *acrIF8–aca2* locus was acquired
100 similarly irrespective of the Aca2 helper plasmid, the number of viable conjugants containing
101 the *acrIF8–Δaca2* plasmid was diminished in the absence of the Aca2 helper plasmid (**Figure**
102 **1A-i**). Toxicity was dependent on the AcrIF8 protein since a plasmid containing a premature
103 stop codon in *acrIF8* did not require the Aca2 helper plasmid (**Figure 1A-ii**). These results
104 suggest that unregulated production of AcrIF8 from its native promoter is toxic to *P.*
105 *carotovorum* in the absence of other ZF40 phage genes, while Aca2 alleviates toxicity.




Figure 1: Aca2 alleviates toxicity of the *acrIF8-aca2* operon. **A)** Conjugation efficiencies of *acrIF8-aca2* operon variants. The *P. carotovorum* recipients contained a separate, non-mobilizable *aca2* expression plasmid (helper plasmid, +*aca2*, also present in *E. coli* donors) or a vector control (-*aca2*). **i.** Transfer of the *acrIF8-aca2* operon compared to an *aca2* deletion (Δ) variant. **ii.** Transfer of the variants in **i.** but with premature stop codons in *acrIF8* (red octagon). **B)** Titres of ZF40 phages with different *acrIF8-aca2* locus variants upon *P. carotovorum* infection. In addition to the variants tested in **A (i., ii.)**, variants also containing a transcriptional terminator (T) downstream from the operon (**iii.**) and variants also containing inactivating point mutations in the -10 region of the promoter (TCTAAG instead of TATAAT; red T-arrow, **iv.**) were tested. Data shown are the mean \pm standard error of the mean (SEM) (n=3). Significance was assessed using Welch's *t*-test corrected for multiple comparisons (Benjamini, Krieger and Yekutieli); ns, $p \geq 0.05$; **, $0.001 \leq p < 0.01$; ***, $p < 0.001$.

We exploited the Aca2 helper plasmid during phage engineering to generate and recover *aca2* deletion phages. The plaque count of *aca2* deletion phages was significantly reduced after infection of *P. carotovorum* lacking Aca2 compared with the Aca2 helper strain (**Figure 1B-i**). Therefore, Aca2 is essential to control *acrIF8-aca2* expression during ZF40 phage replication. To further explore this Aca2 requirement, we created multiple phages with altered *acrIF8-aca2* loci and tested their replication in the presence and absence of the Aca2 helper plasmid. In contrast to the plasmid-based assay, a premature stop codon in *acrIF8* was insufficient to fully remove the dependency of phage propagation on Aca2 (**Figure 1B-ii**). This suggested that an additional effect of Aca2 in the natural phage context is to limit detrimental

129 consequences of uncontrolled *acrIF8-aca2* operon transcription. Introduction of a strong
130 transcriptional terminator²² at the end of the *acrIF8-aca2* operon was insufficient to rescue
131 phage fitness in the absence of Aca2, even if *acrIF8* was mutated (**Figure 1B-iii**). This suggests
132 that uncontrolled read-through transcription (as observed for different *acr* operons^{3,23}) was not
133 solely responsible for the observed toxicity. Interestingly, rare *aca2* deletion phages that
134 replicated without Aca2 had point mutations in the -10 or -35 regions of their *acrIF8-aca2*
135 promoters (**Extended data figure 1B**). This indicated that phage replication in the absence of
136 Aca2 is only possible if transcription from the *acrIF8-aca2* promoter is attenuated. In support
137 of this, an engineered phage variant with point mutations in the -10 region (previously shown
138 to abrogate promoter activity²) replicated efficiently without Aca2 (**Figure 1B-iv**). Overall, our
139 findings demonstrate that Aca2 regulation is crucial for phage replication by limiting toxic
140 AcrIF8 over-production and controlling transcription from the *acrIF8-aca2* promoter.

141


142 **Aca2 binds RNA in the structured *acrIF8-aca2* 5' UTR**

143 To investigate how Aca2 achieves stringent control of *acrIF8-aca2*, we examined the
144 regulatory region of this locus (**Figure 2A**). Previously, we demonstrated that Aca2 binds DNA
145 at an inverted repeat (IR1) in the *acrIF8-aca2* promoter to inhibit transcription. A second,
146 similar inverted repeat (IR2), located downstream of IR1, contributed to *acrIF8* repression
147 despite not being bound by Aca2². We predicted that IR2 is part of the *acrIF8-aca2* 5' UTR
148 and that Aca2 interacts with IR2 on the mRNA. To test this hypothesis, we first determined the
149 transcriptional start site of the *acrIF8-aca2* operon. The transcriptional start site mapped
150 perfectly in relation to strong consensus -35 and -10 promoter elements and, importantly,
151 immediately upstream of IR2 (**Figure 2A, Extended data figure 2A**). Therefore, IR2 is part
152 of the *acrIF8-aca2* mRNA.

153

154 Next, to test for an Aca2–RNA interaction, we incubated purified Aca2 with an RNA
155 oligonucleotide containing IR2 and performed analytical size-exclusion chromatography. This
156 demonstrated an interaction between Aca2 and RNA as a higher molecular weight complex
157 (**Extended data figure 2B**). To further examine RNA binding, we used electrophoretic
158 mobility shift assays (EMSAs) with purified Aca2 and a labelled RNA of the first 60 nt of the
159 *acrIF8-aca2* transcript. A direct dose-dependent interaction was evident by a distinct single
160 shift in migration of the RNA upon increasing Aca2 concentrations (**Figure 2B**), with a
161 dissociation constant (K_D) of 30.2 nM (**Figure 2C**). Aca2 binding to the 5' UTR was specific
162 since no binding occurred to a mutated RNA with a palindrome of identical length and GC
163 content but a different sequence in place of IR2 (**Figure 2D**). To test whether IR2 is sufficient
164 for Aca2 binding to RNA, we performed EMSAs using the previous full-length labelled RNA
165 and competed this binding with an excess of secondary unlabelled RNAs of different lengths
166 (**Figure 2A,E**). IR2 alone was insufficient for Aca2 binding; instead, another inverted repeat
167 located between IR2 and *acrIF8* was necessary to outcompete the full-length RNA (**Figure**
168 **2E**). As this additional inverted repeat encompasses the *acrIF8* ribosomal binding site (RBS),
169 we named it IR-RBS (**Figure 2A**). We further hypothesized that IR2 and IR-RBS form stem-
170 loop structures by sequence complementarity of their half sites. Indeed, the computed
171 minimum free energy RNA structure of the 5' UTR contained dual stem-loops of IR2 and IR-
172 RBS (**Figure 2F**), which we experimentally confirmed using in-line probing (**Figure 2G**).

173 Overall, the 5' UTR of the *acrIF8-aca2* operon forms a secondary structure of two stem-loops
 174 and this RNA is bound specifically by Aca2.
 175



176
 177 **Figure 2: Aca2 binds RNA structural elements within the *acrIF8-aca2* 5' UTR.** A) Overview
 178 of the promoter and 5' UTR of *acrIF8*. Regulatory elements are indicated above the sequence,
 179 inverted repeats (IR) are green. Underneath, the sequences of RNAs used in subsequent
 180 experiments are shown, with IR sequences (bold) and mutations (red). B) EMSA of a
 181 fluorescently labelled 60-nt RNA incubated with increasing [Aca2] (two-fold increments from
 182 6.25–800 nM). C) Dissociation constant (K_D) based on [Aca2] and proportion of bound versus
 183 unbound bands from B. Data shown is the mean \pm SEM (n=3). D) EMSA of a labelled 60-nt
 184 IR2^{mut} RNA with [Aca2] as per B; the 60-nt RNA from B was used as a control at the highest
 185 [Aca2]. E) EMSA with competition of the labelled 60-nt RNA with 200-fold excess of the
 186 indicated unlabelled RNAs of different sizes (see A) and an [Aca2] of 100 nM. F) Minimum free
 187 energy structure of the *acrIF8-aca2* mRNA (first 44 nt). Coloured bases are predicted to be paired
 188 based on the in-line probing result. G) In-line probing of the 44-nt RNA shown in F. RNA =
 189 untreated RNA, OH = alkaline hydrolysis treatment, T1 = RNase T1 treatment, IL = RNA treated
 190 for 40 h in in-line probing buffer. Sizes of T1-treated fragments, which have a G at their 3' end,
 191 are indicated. Coloured lines indicate RNA positions protected from spontaneous hydrolysis and
 192 are consistent with the structure in F.

194 **Aca2 represses *acrIF8* translation by blocking ribosome binding**

195 To examine the regulatory effect of Aca2 binding to the *acrIF8-aca2* 5' UTR, we used a
 196 stepwise *in vitro* transcription and translation approach to enable differentiation of Aca2-
 197 mediated transcriptional repression (through DNA binding at IR1) from post-transcriptional
 198 effects (Figure 3A). We first performed *in vitro* transcription to produce mRNA with the
 199 *acrIF8-aca2* 5' UTR fused to an *eyfp* reporter, then used this mRNA as the template for
 200 separate *in vitro* translation reactions with and without purified Aca2. Without Aca2, eYFP
 201 production efficiently initiated from the *acrIF8-aca2* 5' UTR, whereas Aca2 repressed

202 production (**Figure 3B**). Additionally, Aca2-mediated repression was specific to the 5' UTR
203 since it was abolished by mutation of IR2 (**Figure 3C**), thereby demonstrating that Aca2
204 binding to the 5' UTR represses translation.

205

206 To determine whether Aca2-mediated translational repression occurs *in vivo*, we used a 5'
207 UTR-*eyfp* translational reporter with transcription driven by an inducible T5/*lac* promoter
208 (**Figure 3D**). Because IR1 was absent and IR2 DNA is not bound by Aca2², this setup allowed
209 the examination of post-transcriptional effects of Aca2 binding to IR2 RNA when *aca2* is
210 expressed from a separate plasmid. Fluorescence of eYFP was detected in single cells by flow
211 cytometry. Consistent with our *in vitro* results, *in vivo* expression of *eyfp* from the *acrIF8-aca2*
212 5' UTR was reduced by more than ten-fold by Aca2 (**Figure 3E**). We then used this assay to
213 determine the effects of 5' UTR mutations on basal *eyfp* expression as well as their ability to
214 be repressed by Aca2. IR2 mutations – either one half site, both half sites, or the loop region
215 between the half sites – affected basal expression to varying degrees but, importantly, they all
216 abrogated Aca2-mediated repression (**Figure 3E**). Therefore, IR2 sequence and structural
217 elements are important for translational repression by Aca2.


218

219 Given the operon structure of *acrIF8-aca2*, it was important to determine whether Aca2
220 specifically downregulates *acrIF8* translation without affecting translation of *aca2* itself.
221 Therefore, we modified the reporter construct used above by combining the *acrIF8-aca2* 5'
222 UTR with an artificial *acrIF8-eyfp* operon (i.e. with *eyfp* in place of *aca2*, **Extended data**
223 **figure 3**). In this setup, Aca2 did not post-transcriptionally repress *eyfp* (**Figure 3E**), indicating
224 that Aca2-mediated translational repression of *acrIF8* does not affect *aca2* translation.
225 Altogether, post-transcriptional regulation by Aca2 involves specific recognition of sequences
226 within the 5' UTR and exclusively affects *acrIF8* translation.

227

228 The interaction of Aca2 with IR2 and IR-RBS suggested that translational repression involves
229 RBS occlusion by Aca2, blocking ribosome binding and translation initiation. To test this, we
230 first incubated purified ribosomes with a 60-nt RNA encompassing the *acrIF8-aca2* 5' UTR
231 and the start of *acrIF8* and analysed the association by EMSA. Addition of increasing
232 concentrations of ribosomes led to a single concentration-dependent shift, indicating that the 5'
233 UTR is recognised and bound by ribosomes (**Figure 3F**). However, pre-incubation with Aca2
234 prevented this shift and resulted in a shift similar to that previously seen for the Aca2–RNA
235 interaction (**Figures 3G and 2B**). These results indicate that direct binding of Aca2 to the
236 *acrIF8-aca2* 5' UTR prevents ribosome access to the RBS, thus suggesting a mechanism for
237 direct translational repression.

238



239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262

Figure 3: Aca2 represses translation of *acrIF8*, but not *aca2*, by blocking ribosome access to the 5' UTR. **A)** Schematic of the two-step assay that separates P_{T7}-driven transcription from translation of *eyfp* controlled by the *acrIF8*–*aca2* 5' UTR (TX and TL; *in vitro* transcription and translation, respectively). **B)** *In vitro* translation of purified RNA encoding *eyfp* controlled by the wild-type *acrIF8*–*aca2* 5' UTR, in the absence (red) or presence (blue) of purified Aca2. **C)** Like **B** but with the IR2^{mut} variant of the *acrIF8*–*aca2* 5' UTR (see **Figure 2A**). In **B** and **C**, data shown is the mean (solid lines) ± SEM (shading) (n=3). **D)** Schematic of the *in vivo* translational repression assay involving a reporter plasmid (with translational fusions of P_{T5/lac} with variants of the *acrIF8*–*aca2* 5' UTR with *eyfp*) and a separate *aca2* expression plasmid. **E)** *White bars*: eYFP fluorescence after 20 h of growth using reporter plasmids with the indicated variants of the *acrIF8*–*aca2* 5' UTR (dotted box), or of the wild-type 5' UTR combined with an artificial *acrIF8*–*eyfp* operon (using an *acrIF8* variant with premature stop codons to prevent toxicity). *Blue bars*: Fold-reduction of fluorescence in the presence of a separate *aca2* expression plasmid compared to basal expression in the presence of the corresponding empty vector. Data shown is the mean ± SEM (n=6). Significance was assessed using Welch's *t*-test corrected for multiple comparisons (Benjamini, Krieger and Yekutieli) of unnormalised data ± Aca2. ns, *p* ≥ 0.05; ***, *p* < 0.001. **F)** EMSA of RNA (first 60 nt of *acrIF8*–*aca2* transcript) incubated with ribosomes (two-fold increments from 1.25–320 nM; grey triangle). **G)** EMSA of the same RNA in **F** but first incubated with 200 nM Aca2 (grey bar), followed by addition of purified ribosomes (two-fold increments from 2.5–160 nM; grey triangle) and further incubation. Components and putative complexes formed are indicated between the two gel images; from bottom to top: RNA; RNA with Aca2; RNA with ribosome.


263 **Aca2 uses its multifunctional HTH domain to bind the 5' UTR**

264 Our results demonstrate that Aca2 directly associates with the *acrIF8-aca2* 5' UTR to mediate
265 translational repression by blocking ribosome binding. However, how an HTH domain protein
266 binds RNA and discriminates this from DNA binding is unknown. To directly understand the
267 molecular details of the Aca2–RNA interaction, we performed cryogenic electron microscopy
268 (cryo-EM) of Aca2 incubated with a 42-nt RNA containing IR2 and IR-RBS. Despite initial
269 challenges in reconstruction and 3D classification of this complex due to its small size (~40
270 kDa including the Aca2 dimer and RNA), we ultimately succeeded in solving the structure to
271 2.6 Å resolution by applying the novel deep-learning-based Blush regularisation method in
272 RELION-5²⁴ (**Figure 4A, Extended data figure 4A, Supplementary table 6**). In this
273 structure, the Aca2 dimer is bound to one RNA molecule that forms two stem-loops
274 encompassing IR2 and IR-RBS. This RNA structure is fully consistent with our bioinformatic
275 and in-line probing data (**Figure 2F,G**). Due to their proximity and base-pairing, the two RNA
276 stem-loops resemble one continuous stretch of double-stranded nucleic acid. Strikingly, the
277 major grooves of this dsRNA segment are wider than in typical A-form RNA double helices
278 and more similar to the geometry of a B-form DNA double helix. This suggests that the IR2
279 and IR-RBS helices can stack and distort to structurally mimic the dsDNA target of Aca2.
280 Along this dsRNA segment, one Aca2 monomer binds the IR2 portion and the other Aca2
281 monomer binds the IR-RBS portion. Importantly, the RBS is occluded in this Aca2–dsRNA
282 structure, consistent with inhibition of ribosome binding and translation when Aca2 is bound
283 to the *acrIF8-aca2* 5' UTR (**Figure 3B,H**).

284
285 The overall binding of the Aca2 dimer to dsRNA resembles its DNA binding¹⁸ but with key
286 differences (**Figure 4B**). Insertion of the HTH domains into the dsRNA grooves distorts the
287 protein compared with its conformation when bound to IR1 DNA¹⁸ (**Figure 4B**), suggesting
288 the dual RNA and DNA binding of the Aca2 dimer is enabled through structural plasticity.
289 Despite the asymmetry of the RNA substrate, each monomer contributes a similar set of amino
290 acids to the interaction. For example, S28, R30 and Q33 of each monomer bind to IR2 or IR-
291 RBS, whereas only S31 and Y34 are exclusively involved in binding either IR-RBS or IR2,
292 respectively (**Figure 4C, Extended data figure 4B**). All the aforementioned amino acids that
293 are involved in dsRNA binding are also involved when Aca2 binds DNA at IR1 (**Figure 4D**),
294 although their involvement in binding can differ. R30 exemplifies this as its interaction with
295 IR-RBS (dsRNA) is distinct from the interactions with IR1 (DNA) and IR2 (dsRNA) (**Figure**
296 **4E, Extended data figure 4B**). In addition to dsRNA segments formed by the IR2 and IR-
297 RBS half sites, there are further interactions between Aca2 and the single-stranded loops
298 between the half sites. In particular, D45 of each monomer interacts with guanine nucleotides
299 within each loop (**Figure 4C,E**), explaining the conservation of D45 across Aca2 homologs
300 (**Extended data figure 4C**) despite having no role in DNA binding (**Figure 4D,E**).

301
302 To validate the role of the HTH domain and specific residues in DNA and RNA binding, we
303 generated site-directed mutations (R30A and D45A) and examined their ability to repress eYFP
304 reporters that would only respond to DNA-based (IR1 only) or RNA-based (IR2 and IR-RBS)
305 regulation. Consistent with the structure and amino acid conservation, a D45A mutation had
306 no effect on transcriptional (DNA-based) repression but specifically abrogated RNA-mediated

307 translational repression (**Figure 4F**). In contrast, the R30A mutation eliminated regulation by
 308 Aca2 at both the DNA and RNA levels (**Figure 4F**). Overall, these results demonstrate the
 309 structural basis for Aca2 as both a DNA- and RNA-binding protein by means of a
 310 multifunctional HTH domain, whose amino acid composition and conservation highlight the
 311 importance of RNA-based regulation.
 312



313
 314 **Figure 4: The mode of Aca2 binding to RNA is distinct from its interactions with DNA. A)**
 315 Cryo-EM structure of an Aca2 dimer (of monomers A and B) bound to RNA containing IR2 and
 316 IR-RBS stem-loops. **B)** Overlay of our Aca2–RNA (RNA in purple) cryo-EM structure with the
 317 Aca2–DNA (DNA in white) crystal structure (PDB entry 7VJQ¹⁸). Increasing C_{α} deviation
 318 between RNA- and DNA-bound Aca2 is indicated by a colour gradient from white to red; the $\alpha 3$
 319 recognition helices are labelled. **C)** Aca2–RNA structure rotated by 90° around the horizontal
 320 axis (relative to **A**) and overview of the interactions between Aca2 residues and IR2 and IR-RBS
 321 RNA. **D)** Aca2–DNA complex (equivalent to **C**) and interactions between Aca2 residues and the
 322 IR1 DNA. **E)** Enlarged views of residues Arg30 (R30) and Asp45 (D45) in the Aca2–RNA
 323 complex (IR2 and IR-RBS) and in the Aca2–DNA complex. **F)** Fold-reduction of median eYFP
 324 fluorescence of different *acrIF8–aca2* promoter or 5' UTR variants with Aca2^{wt} or variants
 325 (R30A, D45A), relative to an empty-vector control. To test Aca2 mutations on DNA binding only,
 326 a transcriptional fusion of a promoter variant containing IR1 but a deletion of IR2 to *eyfp* was

327 used. To test Aca2 mutations on RNA binding only, a translational fusion of the *acrIF8-aca2* 5'
328 UTR containing IR2 and IR-RBS to *eyfp* was used (as in **Figure 3D**). Data shown is the mean \pm
329 SEM (n=5) and significance against Aca2^{wt} using Dunnett's multiple comparisons test; ns, $p \geq$
330 0.05; ***, $p < 0.001$.

331


332 **Aca2 restrains an initial rapid Acr burst and accumulation as phage DNA replicates**

333 Our mechanistic data revealed a detailed view of the Aca2-mediated regulatory circuit (**Figure**
334 **5A**). To examine Acr production dynamics and determine contributions of transcriptional and
335 translational repression, we generated a stochastic dynamic model of this circuit (model and
336 parameters in **Methods, Supplementary tables 7 and 8**; see **Supplementary figure 3** for
337 sweeps of model parameters). The model begins with a single phage infection and injected
338 DNA is transcribed into mRNA, which can be translated to AcrIF8 and Aca2. Aca2 represses
339 *acrIF8-aca2* transcription and *acrIF8* translation but not *aca2* translation. There is a 5 min
340 latency period, then the phage genome replicates to a copy number of 50 within 60 min. The
341 model revealed that the regulatory circuit enables AcrIF8 production rate to increase steeply
342 after phage infection and then quickly decline to a constant low level (**Figure 5B**). The result
343 is a rapid, early Acr accumulation in the cell, followed by a gradual on-going increase
344 throughout phage infection (**Figure 5C**). The burst of AcrIF8 production fits with the
345 expectation that Acrs should rapidly inactivate host CRISPR-Cas defences and our model
346 captured *acr* mRNA expression and repression dynamics consistent with previous predictions
347 and experimental data^{3,23} (**Extended data figure 5A**). To determine the contributions of
348 transcriptional (DNA-binding) and translational (RNA-binding) repression, we excluded
349 either, or both, regulatory modes from the model. As expected, without regulation, Acr levels
350 rose quickly and to high levels, demonstrating the importance of regulation in restraining
351 excessive Acr production (**Figure 5D, Extended data figure 5B-D**). Individually, DNA and
352 RNA binding contributed strongly to Acr repression and substantially reduced Acr production
353 compared with the unregulated operon (**Figure 5D, Extended data figure 5B-D**). However,
354 both modes of regulation together were essential for complete tight repression, as this requires
355 not only transcriptional shutoff but also the ability of Aca2 to inhibit translation of mRNAs
356 that are still present or produced at low levels.

357

358 The dual Aca2 control incorporates negative feedback by transcriptional autorepression but
359 also an incoherent feed-forward loop where the transcribed mRNA produces both AcrIF8 and
360 Aca2, but then Aca2 blocks further translation of only *acrIF8*. Similar circuitries have been
361 associated with dosage compensation – enhanced robustness independent of the copy number
362 of the encoding DNA^{25,26}. We therefore hypothesised that, as the phage genome replicates,
363 translational repression is important to control Acr levels by suppressing translation from
364 mRNAs – either produced before the onset of transcriptional repression or as a result of leaky
365 transcription. In agreement, modelling of *acrIF8* expression for a range of final DNA copy
366 numbers showed that RNA-based regulation became more important at copy numbers
367 representative of typical phage replication; under these conditions, AcrIF8 production could
368 not be completely restrained by transcriptional repression alone (**Figure 5E, Extended data**
369 **figure 5E, Supplementary figure 3**). To experimentally test the copy number robustness of
370 the regulatory circuit, we used plasmids with different copy numbers and an *eyfp-aca2* operon

371 (i.e., replacing *acrIF8*) controlled by the native promoter and 5' UTR, or variants lacking DNA-
 372 and/or RNA-based regulation. Without regulation, eYFP (as a proxy for Acr) reached high
 373 levels, scaling uniformly with copy number (**Extended data figure 5F**). In contrast, full
 374 regulation provided gene dosage compensation, reining in Acr levels by ~30 to 100-fold from
 375 low to higher DNA copy number (**Figure 5F**). Only at the lowest copy number was DNA
 376 regulation alone sufficient to reduce Acr to levels observed for complete regulation.
 377 Importantly, RNA regulation was essential for complete control as copy number increased and
 378 alone also strongly suppressed Acr production (**Figure 5F**). Therefore, the Aca2-mediated
 379 regulatory circuit is important to buffer Acr production by compensating expression despite
 380 different phage genome copy numbers. Our modelling and experiments demonstrate how the
 381 dual DNA and RNA binding properties of Aca2 enable an initially high Acr burst (to silence
 382 CRISPR–Cas), then repression and buffering as phage DNA accumulates.
 383



384

385 **Figure 5: Aca2 restraints an initial rapid Acr burst and accumulation as phage DNA**
 386 **replicates.** **A)** Schematic of dual regulation by Aca2. Aca2 represses transcription (TX) of
 387 *acrIF8-aca2* by binding IR1 in the promoter, or translation (TL) specifically of *acrIF8* by binding
 388 stem-loops in the *acrIF8-aca2* 5' UTR. **B)** Stochastic modelling of the AcrIF8 production rate
 389 per cell in the presence of transcriptional and translational regulation over a time span of 60 min
 390 post infection by a single phage. Data shown is the mean (solid line) and standard deviation
 391 (shading) from 200 simulations. Inset = first 10 minutes after infection. **C)** Like **B** but AcrIF8
 392 accumulation over time. **D)** Like **C** but with an unregulated operon (*left*), only DNA-based
 393 (transcriptional) (*middle*) or only RNA-based (translational) (*right*) regulation. The green line
 394 represents full regulation for comparison (same data as in **C**). **E)** Modelling end point data (mean
 395 Acr molecules per cell at 60 min) for scenarios where phages replicate to final copy numbers of
 396 1, 10, 50 or 100 under different regulatory states (see **Extended data figure 4E** for full time
 397 courses). Further parameter sweeps for the model in **Supplementary figure 3**). **F)** AcrIF8
 398 production (measured as median eYFP fluorescence by flow cytometry) from plasmids with
 399 different copy numbers (the origins of replication and resulting copy numbers are indicated) for
 400 the same regulatory states as in **E**. In **E** and **F**, error bars indicate standard deviation.

401


402 **Post-transcriptional regulation is widespread in the Aca2 family**

403 The importance of Aca2 dual transcriptional and post-transcriptional repression for controlling
404 AcrIF8 dynamics in phage ZF40 led us to hypothesise that this mode of regulation would be
405 widespread. We analysed a non-redundant set of 147 operons containing *aca2* and at least one
406 other (possibly *acr*) gene for the presence of potential regulatory motifs. The known *acr* genes
407 in these operons were diverse inhibitors of type I and II CRISPR–Cas systems (**Figure 6A**).
408 Strikingly, we predicted potential RNA motifs upstream of more than half of these operons
409 with high confidence using stringent criteria, a proportion that further increased with less
410 stringent thresholds. The motifs were classified into two distinct groups named according to
411 the phyla in which they predominantly occurred: the proteo-motif and the actino-motif (in
412 proteo- and actinobacteria or their associated mobile genetic elements) (**Figure 6B**). The motif
413 distribution correlated with the phylogenetic clustering of Aca2 proteins, supporting functional
414 coevolution between Aca proteins and RNA motifs (**Extended data figure 6A**). The motifs
415 were located between the predicted transcription start site and the start codon, consistent with
416 a role in RNA-based regulation and the arrangement in phage ZF40 (**Figure 6C, Extended**
417 **data figure 6B**). Both the proteo- and actino-motifs were always associated with a putative
418 DNA binding motif upstream from the transcription start site, which overlapped with the -35
419 and -10 regions, again consistent with transcriptional repression and the placement of IR1 in
420 phage ZF40 (**Figure 6C, Extended data figure 6B**). The proteo-motif consists of two stem-
421 loops, the upstream one of which typically starts immediately after the predicted transcription
422 start site and displays structural conservation; this stem-loop is equivalent to IR2 in ZF40. The
423 second stem-loop is equivalent to IR-RBS in ZF40 and, based on sequence conservation and
424 distance to the start codon, appears to occlude the RBS (**Figure 6D**). The actino-motif also
425 contains two stem-loops, again resembling IR2 and IR-RBS in ZF40 (**Extended data figure**
426 **6C**). The common occurrence of these Aca2-associated proteo- and actino-motifs for DNA and
427 RNA binding highlights that dual transcriptional and translational control is widespread in the
428 Aca2 family.

429

430 Since functional interactions between Aca2 and the RNA and DNA motifs should be evident
431 in co-evolutionary signals, we tested whether nucleotide changes in the regulatory regions co-
432 vary with amino acid substitutions. Many amino acids involved in Aca2–DNA and/or Aca2–
433 RNA interactions, including R30 and D45, are invariably conserved across homologs and do
434 not co-vary. In contrast, Y34 in ZF40 Aca2, which interacts with DNA and RNA (**Figure 6E**),
435 is frequently substituted in other homologs with an arginine. This amino acid exhibits
436 statistically significant co-variation with specific nucleotides within DNA (IR1) and RNA
437 (IR2) (**Figure 6F, Extended data figure 6D**). Therefore, co-variation further supports that
438 Aca2 proteins have co-evolved to specifically interact with bases in both DNA (IR1) and RNA
439 (IR2). Collectively, our bioinformatic analyses indicate that HTH interactions with specific
440 RNA and DNA motifs are a conserved widespread feature of Aca2 proteins in different
441 bacterial taxa and demonstrates the broad utility of this regulatory strategy.

442



443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

Figure 6: DNA and RNA binding sites are conserved in *aca2*-containing operons and co-vary with the Aca2 protein sequence. **A)** Four representative *aca2*-containing operons including the upstream regions (purple) and variable *acr* genes (shades of pink). **B)** Distribution of *aca2*-containing operons with any (proteo- or actino-) motif (top), proteo-motif (middle) or actino-motif (bottom) across bacterial phyla. “No host found” indicates a motif present in a phage with no known host. **C)** Position plot displaying the relative locations of the DNA motif (corresponding to IR1 in ZF40), the proteo-motif for RNA-based regulation and the start codon. **D)** Structure and sequence conservation within the proteo-motif and its upstream DNA motif. Coloured boxes represent the presence of any nucleotide at this position, with the frequency indicated by the shade as described on the right; coloured letters indicate the frequency of a specific nucleotide at this position. Black bonds indicate base complementarity, grey shading indicates co-varying positions. **E, F)** Example of co-variation between Aca2 and associated DNA/RNA sequences in phage ZF40 (**E**) and *S. xiamenensis* (**F**). Y34 of ZF40 interacts with the blue nucleotides in the DNA and RNA motifs; when Y34 is substituted with R34, as in *S. xiamenensis*, the interacting nucleotides (red) co-vary. Note that the corresponding nucleotides in the RNA motif do not co-vary because the U at this position is complementary to either A or G. See **Extended data figure 6D** for more details.

Discussion

Like most other HTH proteins, members of the Aca family were understood to function solely as DNA-binding transcriptional regulators²⁻⁵. We have discovered a mechanism whereby a

466 simple HTH domain protein binds to both specific DNA and RNA motifs for dual
467 transcriptional and translational control. In addition to its role in transcriptional repression of
468 the *acrIF8-aca2* operon, we made the surprising discovery that Aca2 binds mRNA and
469 represses *acrIF8* translation. The necessity of this dual regulation is explained by the following
470 model (see also **Figure 5A**). Upon phage DNA injection, AcrIF8 is rapidly produced at a high
471 enough rate to prevent an effective CRISPR–Cas response^{15,21}. Aca2 subsequently binds IR1
472 to repress further transcription. However, mRNAs have already been produced, and keep being
473 produced due to leaky transcription and increasing phage genome copies. As Aca2
474 accumulates, it binds the conserved IR2 and IR-RBS RNA structures, occluding ribosome
475 binding and inhibiting *acrIF8* translation from these mRNAs. Aca2 is still produced and limits
476 further AcrIF8 production. This simple, yet elegant regulatory circuit allows strong and rapid
477 Acr production to silence CRISPR–Cas, whilst limiting overall AcrIF8 levels to prevent
478 toxicity. Importantly, the regulatory circuit is robust to changes in copy number, enabling
479 buffered regulation during phage genome replication. The importance of this strategy is
480 highlighted by the wide distribution of *aca2*-associated regulatory elements in 5' UTRs and the
481 conservation and evolutionary co-variation of protein and nucleic acid sequences.

482

483 Due to the simplicity and modularity of the dual DNA and RNA binding regulatory mechanism
484 of Aca2, we predict similar functions for many of the other Aca families and, indeed, dimeric
485 HTH proteins in general – despite the predominant notion that they are solely DNA binders.
486 Dual-functional proteins with HTH or similar domains that bind DNA and RNA have long
487 been thought to be rare, one example being Bicoid in *Drosophila*. Bicoid contains an HTH-
488 related homeodomain and controls embryogenesis as a monomer through DNA and RNA
489 binding²⁷. There are more examples of complex multi-domain proteins with a winged HTH
490 domain that solely bind RNA, including La^{28,29} and Roquin^{30,31} in eukaryotes and SelB, which
491 occurs in all domains of life^{32,33}. Therefore, the dual regulatory mechanism we have defined
492 for a simple dimeric HTH protein is distinct and potentially widespread since these are
493 ubiquitous transcriptional regulators, particularly in bacteria. Support that HTH domain
494 proteins have broader dual regulatory roles is evident from recent work in *Staphylococcus*
495 *aureus* where some DNA-binding proteins that also bind transcripts were identified; however,
496 their mechanism(s) and any regulatory consequences are not well established^{34,35}. In addition,
497 several recent studies in eukaryotes suggest that many (non-HTH) transcription factors may
498 have additional roles by interacting with diverse RNAs^{36,37}. While these findings emphasize an
499 underappreciated RNA-binding role for transcription factors, the apparent promiscuity of these
500 interactions starkly contrasts the specificity of Aca2. We speculate that the dual regulatory
501 mode shown for Aca2 could originate readily through DNA duplication and adaptation of
502 nucleic acid binding sites and may require only slight co-evolutionary adjustments in the HTH
503 domain. Indeed, despite its compactness and basic architecture, the Aca2 HTH domain is
504 remarkably versatile – not only dual-functional with regards to the type of nucleic acid bound,
505 but also engaging in three different molecular interactions with its targets (distinct contacts
506 with DNA, and RNA of IR2 and IR-RBS). The evolution of this circuitry is likely to be
507 facilitated by the modularity of *aca2* and its regulatory sites, which can be combined with
508 various *acr* or other genes, such as *eyfp* in our experiments. This exchangeability offers

509 possibilities for the use of synthetic circuits involving Aca2 regulation for tight control of gene
510 expression.

511

512 In conclusion, our study has discovered a dual-functional Aca protein that binds DNA and
513 RNA to allow appropriate Acr production by phages in their arms race with bacterial CRISPR–
514 Cas systems. We anticipate that similar dual regulation will be widespread – not only in
515 different *acr–aca* operons but for other HTH proteins in general.

516 **Methods**

517

518 **Bacterial strains, phages, plasmids and oligonucleotides**

519 Strains, phages, plasmids and oligonucleotides used in this study are listed in **Supplementary**
520 **Tables 1, 2, 3 and 4**, respectively, with construction details provided if applicable. Unless
521 otherwise indicated, *E. coli* and *P. carotovorum* strains were grown in liquid LB medium or on
522 plates of LB with 1.5% agar (LBA) at 37°C and 30°C, respectively. Phage overlay assays
523 further involved soft agar (0.35%) and phages were stored in phage buffer (10 mM Tris-HCl
524 pH 7.4; 10 mM MgSO₄; 0.01% (w/v) gelatine). Antibiotics were used as appropriate at the
525 following concentrations: ampicillin (Ap), 100 µg/mL; chloramphenicol (Cm), 25 µg/mL;
526 kanamycin (Km), 50 µg/mL; gentamycin (Gm), 30 µg/mL. The supplement 5-aminolevulinic
527 acid (ALA) was used at 50 µg/mL; isopropyl-β-D-1-thiogalactopyranoside (IPTG) and
528 arabinose were used at the concentrations indicated below.

529

530 **DNA isolation and manipulation**

531 Plasmid DNA was isolated using the Zyppy Plasmid Miniprep Kit (ZymoResearch) and all
532 plasmids were confirmed by Sanger sequencing. Restriction digests, ligations, *E. coli*
533 transformations and agarose gel electrophoresis were performed using standard techniques.
534 Transformation of *P. carotovorum* was carried out by electroporation using a Bio-Rad
535 GenePulser Xcell system (set to 1,800 V, 25 µF, 200 Ω) in Bio-Rad electroporation cuvettes
536 with 0.1 cm electrode gap, followed by 2 h recovery in LB medium at 30 °C at 180 rpm. DNA
537 from PCR and agarose gels was purified using the Illustra GFX PCR DNA and Gel Band
538 Purification Kit (GE Healthcare). Polymerases, restriction enzymes and T4 ligases were
539 obtained from New England Biolabs or Thermo Scientific.

540

541 **Conjugation efficiency assay**

542 Overnight cultures of donor *E. coli* ST18 strains with plasmids encoding *acrIF8-aca2* locus
543 variants (pPF2368, pPF2383, pPF2386 and pPF2952) and the arabinose-inducible Aca2
544 expression vector (pPF1532) were prepared in LB with ALA, Ap, Km and 0.2% arabinose, and
545 adjusted to an OD₆₀₀ of 1. The cells were washed by two rounds of centrifugation at 13,000 ×
546 g followed by resuspension in LB supplemented with ALA to remove antibiotics. The washed
547 ST18 cultures were then concentrated 10-fold by centrifugation. Ten µL of the concentrated
548 cultures was plated on LBA with ALA, Ap and 0.2% arabinose and mixed with 10 µL of
549 recipient *P. carotovorum* PCF425 overnight cultures carrying the *aca2* expression plasmid
550 (pPF1532) or its empty vector control (pBAD30). These mating spots were incubated at 30°C
551 overnight and transferred to 1 mL PBS. Ten-fold serial dilutions of the cell suspensions were
552 made, and 10 µL of each dilution were plated on LBA with Ap and 0.2 % arabinose with and
553 without Km, whose colony counts yielded concentrations of transconjugants and total
554 recipients (CFU/mL), respectively. The conjugation efficiencies were calculated as
555 transconjugants divided by total recipients.

556

557 **Generation of phage mutants**

558 The approach for engineering the phage ZF40 genome is outlined in **Extended data figure**
559 **1A**. ZF40 genomes were edited by recombination and counterselection. One hundred µL of

560 phage ZF40 lysate (10^9 – 10^{10} PFU/mL) was mixed with soft LBA and 100 μ L of overnight
561 cultures of *P. carotovorum* PCF425 carrying a homologous recombination template +
562 counterselection plasmid as described in **Supplementary tables 2 and 3**. These plasmids
563 contained an insert with two ~200 bp homology flanks, and additionally encoded a *P.*
564 *carotovorum* type I-E CRISPR spacer targeting the region between the two homology flanks
565 on the phage genome. The phage–host mixture was then poured onto LBA plates, allowed to
566 dry for 10 min, inverted, and incubated overnight at 25°C. After incubation, plaques were
567 picked using a pipette tip and dissolved in 100 μ L phage buffer. The picked plaques were
568 screened for the insert using PCR (primers PF4585 and PF4716). Positive plaques were plated
569 with soft LBA and PCF425 carrying the counterselection plasmid again to remove potentially
570 remaining WT phages. This re-plating of edited ZF40 was repeated three times to ensure a pure
571 phage population. After another round of PCR screening, the sequence was confirmed by
572 Sanger sequencing. The plaque which showed the expected sequence was then amplified to a
573 new phage stock using the phage stock preparation protocol below.

574

575 **Determination of phage titres**

576 One hundred μ L of *P. carotovorum* overnight culture and 4 mL of soft LBA were first poured
577 on an LBA plate. Drops of 5 μ L of 10-fold phage dilutions were then spotted on the solidified
578 agar. After the spots dried, the plate was inverted and incubated at 25°C overnight. After
579 incubation, plaques of the lowest dilution with clear single plaques were counted to calculate
580 the titre. When *Aca2* complementation was required, the overnight culture of PCF425 with an
581 *aca2* expression plasmid (pPF2840) or the corresponding empty vector (pPF2839) were
582 prepared with 0.1 mM IPTG, which was used to inoculate the 4 mL soft LB-agar above and
583 plated on a 0.1 mM IPTG LB-agar plate.

584

585 **Phage stock preparation**

586 A mix of 4 mL soft LBA and 100 μ L PCF425 overnight culture was inoculated with the desired
587 ZF40 variant by picking a single plaque. When inoculating Δ *aca2* variants, an overnight culture
588 of PCF425 carrying an *Aca2*-complementation plasmid (pPF2840) with 0.1 mM IPTG was
589 used. The inoculated soft LBA was then poured onto an LBA plate and incubated at 30 °C.
590 Using a sterile glass slide, the soft LBA from the plate was collected into a chloroform-resistant
591 JA20 centrifuge tube. Remaining phage was collected from the plate by washing with 3 mL
592 phage buffer. Next, 0.5 mL of NaHCO₃-saturated chloroform was added to the centrifuge tube,
593 and it was vortexed for one minute. This was followed by centrifugation at $2,219 \times g$ at 4°C
594 for 20 min. After centrifugation, the supernatant was collected in a glass vial and 100 μ l of
595 chloroform were added for sterility.

596

597 **Sequence and structural analyses**

598 DNA sequence analyses were performed using Geneious Prime (<https://www.geneious.com>).
599 and Clustal Omega was used for sequence alignments³⁸. Protein BLAST
600 (<https://blast.ncbi.nlm.nih.gov>) was used for identification of *Aca2* homologs. Promoter
601 elements were identified by comparison to consensus motifs or using the De Novo DNA
602 server³⁹ and BPROM⁴⁰. RNA secondary structures were predicted using CoFold⁴¹ or
603 RNAfold⁴².

604

605 **5' rapid amplification of cDNA ends**

606 Prior to 5' rapid amplification of cDNA ends (5' RACE) of the *acrIF8-aca2* operon, total RNA
607 was extracted from an overnight culture of *P. carotovorum* ZM1 (a lysogen containing phage
608 ZF40) using the RNeasy Kit (Qiagen), followed by treatment with Turbo DNase (Thermo
609 Fisher) according to the manufacturer's instructions. 5' RACE was performed using template-
610 switching reverse transcriptase (NEB) according to the manufacturer's instructions. Briefly,
611 the reverse transcription primer PF7786 was annealed to its RNA template, followed by reverse
612 transcription and template switching using the template-switching oligo (TSO) PF7784. Next,
613 the 5' region of the *acrIF8-aca2* transcript was amplified by PCR using the TSO-specific
614 primer PF7785 and the *acrIF8-aca2*-specific reverse primer PF7787. The PCR product was
615 gel-purified and Sanger-sequenced using PF7787.

616

617 **Analytical size-exclusion chromatography**

618 Aca2 for analytical size-exclusion chromatography was expressed in *E. coli*
619 BL21(DE3) Δ *slyD*⁴³ transformed with pTRB627¹⁶ allowing expression of a His-SUMO-Aca2
620 fusion protein. Overnight cultures were re-seeded 1:100 into 2 L baffled flasks containing 1 L
621 2 \times YT. Cells were grown at 160 rpm, 37 °C, until an OD₆₀₀ of 0.3 was reached and then at
622 25°C until an OD₆₀₀ of 0.6. Expression was induced by the addition of IPTG (1 mM), then cells
623 were left to grow overnight at 16°C, with shaking at 160 rpm. Following overnight expression,
624 bacteria were harvested by centrifugation at 4,200 \times g, 4°C, and the pellets were resuspended
625 in buffer A [20 mM Tris-HCl (pH 7.9), 500 mM NaCl, 5 mM imidazole, and 10% glycerol].
626 Cells were lysed by sonication and then centrifuged at 45,000 \times g, 4°C. The clarified lysate
627 was passed down a HisTrap HP column (Cytiva) using a peristaltic pump. The resin-bound
628 protein was first washed for 10 column volumes (CV) with buffer A, followed by 10 CV of
629 buffer B [20 mM Tris-HCl (pH 7.9), 100 mM NaCl, 35 mM imidazole, and 10% glycerol] and
630 then eluted directly onto a HiTrap Q HP column (Cytiva) with buffer C [20 mM Tris-HCl (pH
631 7.9), 100 mM NaCl, 250 mM imidazole, and 10% glycerol]. The Q HP column was washed
632 briefly with 5 CV of buffer D [20 mM Tris-HCl (pH 7.9), 100 mM NaCl, 5 mM imidazole, and
633 10% glycerol], and then transferred to an Äkta Pure (Cytiva). Proteins were separated using an
634 elution gradient from 100% buffer D to 40% buffer E [20 mM Tris-HCl (pH 7.9), 1 M NaCl,
635 and 10% glycerol]. Fractions corresponding to the chromatogram protein peak were pooled
636 and incubated overnight at 4 °C with hSEN2 SUMO protease to cleave the N-terminal 6 \times His-
637 SUMO tag from recombinant Aca2. The next day, the sample was passed through a second
638 HisTrap HP column via a peristaltic pump, then washed for 2 CV with buffer A. The flow-
639 through and wash fractions containing untagged Aca2 were collected and concentrated, then
640 loaded onto a HiPrep 16/60 Sephacryl S-200 size exclusion column (Cytiva) connected to an
641 Äkta Pure, in buffer S [50 mM Tris-HCl (pH 7.9), 500 mM KCl, and 10% glycerol]. Fractions
642 corresponding to the chromatogram peak were analyzed by SDS-PAGE, with optimal fractions
643 pooled and dialyzed overnight at 4°C into buffer X [20 mM Tris-HCl (pH 7.9), 150 mM NaCl,
644 and 2.5 mM dithiothreitol (DTT)], then flash-frozen in liquid N₂ for storage at -80 °C.

645

646 Calibration curves for a Superose 6 10/300 GL size exclusion chromatography (SEC) column
647 (Cytiva, discontinued) were generated using appropriate combinations of commercially

648 available low and high molecular weight kit proteins (Cytiva) for best resolution. The column
649 was equilibrated in buffer A [20 mM Tris-HCl (pH 7.9), 150 mM KCl]. For analysis, protein,
650 RNA (PF5021) or mixed samples were manually loaded into a 100 μ L capillary loop in their
651 respective storage buffers at appropriate concentrations to generate a clear UV signal;
652 generally, 1 mg/mL was sufficient. Samples were injected onto the column using buffer S at a
653 flow rate of 0.5 mL/min for fractionation across 1.2 CV.

654

655 **Protein and probe preparation for electrophoretic mobility shift assays**

656 Aca2 protein for electrophoretic mobility shift assays (EMSAs) was produced as previously
657 described². For EMSAs, 5'-IRDye-800CW-labelled or unlabelled RNA probes containing the
658 *acrIF8-aca2* 5' UTR or parts thereof (see **Supplementary Table 5**) were obtained from IDT.
659 RNA was diluted in DEPC-treated water and treated by heating to 95°C, followed by rapid
660 cooling on ice.

661

662 **Electrophoretic mobility shift assays**

663 RNA EMSAs involved 10 μ L reactions containing 20 mM HEPES-NaOH (pH 7.5), 100 mM
664 NaCl, 0.1 mM TCEP, 5 mM MgCl₂, 2 nM labelled RNA probe and purified Aca2^{wt} (or mutant
665 variants thereof) at the concentrations indicated in the figure legends. Binding reactions were
666 incubated for 15 min at room temperature in the dark. For competition assays involving
667 unlabelled probes, excess unlabelled probe (final concentration 200 nM) was incubated with
668 Aca2 prior to addition of 1 nM of the labelled probe. For competition experiments involving
669 *E. coli* ribosomes (New England Biolabs), Aca2 was first incubated with the labelled probe for
670 15 min, followed by addition of ribosome and further incubation for 15 min. After incubation,
671 2.5 μ l loading dye (0.5 \times TBE (45 mM Tris (pH 8.3) 45 mM boric acid, 1 mM EDTA), 34%
672 glycerol (v/v), 0.2% bromophenol blue (w/v)) was added and samples were loaded on 8%
673 polyacrylamide gels (19:1 acrylamide/bis acrylamide (Bio-Rad), 0.5 \times TBE, 2.5% (v/v)
674 glycerol, 0.6 mg/ml ammonium persulfate, 0.05% (v/v) tetramethylenediamine) which had
675 been pre-run for at least 30 min at 4°C. Gel electrophoresis was performed at 100 V and 4°C
676 in the dark for ~1.5 h. RNA was imaged at 800 nm using the LI-COR Odyssey Fc imaging
677 system and Image Studio software.

678

679 **In-line probing**

680 For in-line probing of the P³²-labelled RNA PF5024, ~0.2 pmol was incubated for 40 h at room
681 temperature in 1 \times in-line probing buffer (50 mM Tris-HCl, pH 8.3, 20 mM MgCl₂, 100 mM
682 KCl). Ladders were prepared using the RNase T1 Kit (Ambion). For the alkaline ladder, ~0.2
683 pmol P³²-labeled RNA was denatured for 5 min at 95°C in alkaline hydrolysis buffer. For
684 RNase T1 ladders, ~0.2 pmol P³²-labeled RNA and 10 μ g of yeast RNA was incubated in 1 \times
685 sequencing buffer for 1 min at 95°C, transferred to ice and further incubated with 0.1 U RNase
686 T1 for 5 min at 37°C. All reactions were prepared in 10 μ l volumes and were stopped by adding
687 10 μ l colourless gel-loading solution (10 M urea, 1.5 mM EDTA, pH 8.0) on ice. The reactions
688 were analysed by electrophoresis on 15% PAAG-8M urea gels. The gels were dried, exposed
689 to a storage phosphor screen, and analysed using an Amersham Typhoon imaging system.

690

691 ***In vitro* transcription**

692 To generate suitable templates for *in vitro* transcription, plasmids pPF2435 (wild-type 5' UTR)
693 and pPF2437 (IR2^{mut} 5' UTR) were digested with HindIII and the linearized plasmids were
694 purified by phenol-chloroform-isoamyl alcohol extraction. RNA was synthesized using the
695 HiScribe T7 Quick High Yield RNA Synthesis Kit (New England Biolabs) according to the
696 manufacturer's instructions with subsequent DNase I treatment. Synthesized RNA was purified
697 by LiCl precipitation. Purity and integrity of RNA were confirmed using a NanoDrop One
698 Spectrophotometer (Thermo Fisher) and the Agilent 2100 Bioanalyzer system with an RNA
699 Nano chip.

700

701 ***In vitro* translation**

702 *In vitro* translation of RNA generated by *in vitro* transcription was performed using the
703 PURExpress *In Vitro* Protein Synthesis Kit (New England Biolabs). Reactions were assembled
704 according to the manufacturer's instructions. As the template for translation, 1.15 µg of in-
705 vitro-transcribed RNA was used. Aca2 was supplemented at 10-fold molar excess over RNA
706 and murine RNase inhibitor (New England Biolabs) was supplemented at 20 U per reaction.
707 Reactions were assembled in white LightCycler 480 96-well v-bottom plates (Roche) and
708 eYFP fluorescence was monitored in a Varioskan LUX Microplate Reader by top reads every
709 5 min for 16 h, with excitation set to 513 nm and emission to 531 nm, a measurement time of
710 300 ms, and an excitation bandwidth of 5 nm.

711

712 **Reporter assays**

713 Reporter assays were used to determine the effect of *aca2* expression on different *acrIF8-aca2*
714 5' UTR variants. Each 5' UTR reporter plasmid was tested with an *aca2* expression plasmid
715 (pPF1532) or the corresponding empty vector (pBAD30). Overnight starter cultures of *P.*
716 *carotovorum* strains containing plasmids were grown in 96-well plates in an IncuMix incubator
717 shaker (Select BioProducts) at 1,200 rpm at 30°C. The OD₆₀₀ for each was adjusted to 0.05 in
718 LB medium containing the appropriate antibiotics, and IPTG and arabinose were added to final
719 concentrations of 50 µM and 0.05% (w/v), respectively. After 20 h of growth, fluorescence of
720 plasmid-encoded eYFP was measured by flow cytometry using a BD LSRFortessa cell
721 analyzer. Cells were gated based on forward and side scatter and median fluorescence intensity
722 of eYFP was detected using a 530/30-nm bandpass filter and detector at 600 V. Measurements
723 for a control strain containing empty vectors were subtracted from the other samples to account
724 for background fluorescence.

725

726 **Aca2-RNA complex formation for cryo-EM**

727 The RNA probe PF5022 was dissolved in water at 426 µM. The RNA was folded at a final
728 concentration of 250 µM in 20 mM Tris-HCl pH 7.4 by heating to 95°C for 3 min and reducing
729 the temperature to 22°C over 10 min. MgCl₂ was then added to final concentration 10 mM.
730 Folded RNA (8 µL) was mixed with 6.9 µL of 8 mg/mL Aca2 protein (produced based on a
731 previously described protocol²) and 1.1 µL of water and incubated at 22°C for 15 min, giving
732 a 1:1 molar ratio of RNA to protein dimer in final buffer (18.6 mM Tris-HCl pH 7.4, 100 mM
733 NaCl, 4.3 mM MgCl₂). For cryo-EM grid preparation, a freshly glow-discharged (60 s at 25
734 mA) Cu300 R1.2/1.3 holey carbon grid (Quantifoil) was mounted in the chamber of a Vitrobot

735 Mark IV (Thermo Fisher Scientific) maintained at 12°C and 100% humidity. Four µL of Aca2–
736 RNA complex was applied and immediately blotted using Ø55 grade 595 filter paper (Ted
737 Pella) and plunged into liquid ethane.

738

739 **Cryo-EM data collection**

740 Cryo-EM data were collected using the Thermo Scientific Titan Krios G3i cryo TEM at
741 MIT.nano using a K3 direct detector (Gatan) operated in super-resolution mode with 2-fold
742 binning, and an energy filter with slit width of 20 eV. Micrographs were collected automatically
743 using EPU in AFIS mode, yielding 11,232 movies at 165,000 × magnification with a real pixel
744 size of 0.5309 Å, with defocus ranging from -0.8 µm to -1.5 µm with an exposure time of
745 1.33 s, fractionated into 40 frames and a flux of 15.3 e⁻/pix/s giving a total fluence per
746 micrograph of 72.2 e⁻/Å².

747

748 **Cryo-EM data processing**

749 Our cryo-EM data processing workflow is shown in **Supplementary figure 1**. All cryo-EM
750 data were processed using RELION⁴⁴. Movies were corrected for motion using the RELION
751 implementation of MotionCor2, with 6x4 patches and dose-weighting. CTF parameters were
752 estimated using CTFFIND-4.1. Particle picking was done using Topaz with the general
753 model⁴⁵, yielding 6,449,886 particles. One round of 2D classification was performed with the
754 VDAM algorithm to select 1,743,613 higher-quality particles well resolved from their
755 neighbours. An initial model generated by the VDAM algorithm in RELION from these
756 particles suffered from anisotropy, and 3D classification and/or refinement efforts based on
757 this model failed to converge, generating reconstructions with severe overfitting. We applied a
758 new algorithm²⁴ that uses regularization by denoising (Blush regularization) to overcome this
759 difficulty. 3D classification with Blush regularization produced one class containing 699,000
760 particles with recognizable protein and RNA features, which after refinement was used as a
761 better initial model for a second 3D classification. A single class (1,017,000 particles) was
762 selected for CTF refinement and particle polishing, and was refined to 2.83 Å resolution. 3D
763 classification without alignment (T=192, no Blush regularization) allowed selection of 301,832
764 particles with more well-defined features, which were refined with Blush regularization to
765 produce a final map at 2.6 Å resolution free of streaking artefacts and with features consistent
766 with the estimated resolution. Resolution is reported using the gold-standard Fourier Shell
767 Correlation with 0.143 cutoff (**Supplementary figure 2**). See **Supplementary table 6** for
768 collection, refinement and validation statistics.

769


770 **Cryo-EM model building**

771 The crystal structure of Aca2 bound to DNA (PDB 7VJQ) was docked into the cryo-EM
772 density, the DNA was removed, and the RNA was built *de novo* and the protein side chains
773 adjusted manually using Coot⁴⁶. The model was refined first using ISOLDE⁴⁷, then with
774 PHENIX real_space_refine⁴⁸, just performing one macro-cycle. Figures were generated using
775 UCSF ChimeraX.

776

777 **Mathematical modelling of the *acrIF8–aca2* operon**

778 To describe the *acrIF8–aca2* operon as a mathematical model, we made the following
 779 assumptions: the *acrIF8–aca2* mRNA (*RNA*) is produced at a rate α and can produce AcrIF8
 780 (*Acr*) and Aca2 (*Aca*) by translation at rate constants β and θ , respectively. The Aca2 dimer
 781 can bind to mRNA and form a complex RNA_{Aca} with an association constant a_{RNA} and a
 782 dissociation constant d_{RNA} . The complex RNA_{Aca} is unable to produce *Acr* whereas production
 783 of *Aca* is unaffected. Degradation of *RNA* or RNA_{Aca} occurs with a rate constant ϕ . Degradation
 784 of RNA_{Aca} liberates the bound Aca2. In addition, the *DNA*, representing the transcriptionally
 785 active state, can be converted into the transcriptionally inactive state DNA_{Aca} , and vice versa,
 786 with the binding and dissociation constants a_{DNA} and d_{DNA} , respectively. The onset of DNA
 787 replication relative to the time of infection ($t = 0$) is determined by a latent period. We consider
 788 replication of *DNA* and DNA_{Aca} by using a population model (competitive Lotka-Volterra
 789 equation) with replication rate r and DNA capacity DNA^{max} . Replication of DNA_{Aca} liberates
 790 the bound Aca2. For concentrations, one molecule per cell was assumed to equate to 1 nM^{49} .
 791 The above processes are described by the following reactions:



806 To implement the stochastic simulations from the above chemical reactions using the Gillespie
 807 Algorithm⁵⁰, we assigned a propensity to each reaction as per **Supplementary Table 7**. The
 808 Gillespie Algorithm randomly selects a reaction based on its propensity at each step of the
 809 simulation. Then, it updates the copy number (increase or decrease) by one molecule at a time
 810 while the Algorithm keeps track of all changes in chemical species over time. Python was used
 811 to implement the Gillespie Algorithm and generate stochastic trajectories of the chemical
 812 reactions. The nominal values used for the simulations are listed in **Supplementary table 8**.
 813 Parameter sweeps were performed to test the robustness of the parameter values; the results of
 814 parameter sweeps for the number and production rate of AcrIF8 molecules can be found in
 815 **Supplementary Figure 3**. To simulate DNA replication during the lytic cycle, we only
 816 considered individual phage infections, and the increase in DNA molecules was set to increase
 817 exponentially to the level DNA^{max} as specified in the text.

818

819 **Plasmid copy number assays**

820 *E. coli* ST18 carrying plasmids with different origins of replication and the *eyfp-aca2* operons
821 controlled by different variants of the *acrIF8-aca2* promoter was grown overnight at 30°C in
822 a plateshaker. Cultures were examined for eYFP fluorescence by flow cytometry as described
823 above. To correlate fluorescence with the plasmid copy number, the OD₆₀₀ of the overnight
824 cultures was adjusted to 0.5 and plasmids were extracted as described above. Plasmid
825 concentrations were determined by Qubit and the copy numbers per cell calculated based on
826 the expected number of cells at an OD₆₀₀ of 0.5 (4×10^8), the concentration of the extracted
827 plasmid and the mass of the individual plasmid molecules.

828

829 **Bioinformatic identification *aca2* operons and their regulatory 5' UTRs**

830 The dataset used for the bioinformatic analysis *aca2*-containing operons was based on a
831 previous study⁴. The 256 operons retrieved with the pipeline described in the current study
832 were clustered at a sequence identity threshold of 99% to remove redundant operons with cd-
833 hit (version 4.8.1)⁵¹. After this, 184 *Aca2* operons remained, of which 147 contained at least
834 one other gene in addition to *aca2*. To build a seed alignment of the regulatory regions, seven
835 manually identified sequences² were used. First, the start codon plus 85 upstream nucleotides
836 were extracted from each sequence. Second, the seven sequences were aligned and their
837 consensus secondary structure determined with LocARNA 2.0⁵². Covariance model analysis
838 was conducted using the Infernal software (version 1.1.3)⁵³. A model was built from the
839 alignment using *cmbuild* and *cmcalibrate* with standard parameters. With the resulting
840 covariance model, the 184 non-redundant *aca2* operons were searched using *cmsearch* with a
841 stringent E-value threshold of 0.001. With the resulting structural alignment, a second
842 covariance model was built. This model was used to search the *aca2* operons with the same
843 parameters. The result of the second search was defined as a high confidence set, due to the
844 low E-value thresholds. To identify novel RNA motifs, 75 nt in front of the start codon from
845 all non-redundant operons were extracted and used as an input for the *cmfinder* software
846 (version 0.4.1.18)⁵⁴. The resulting potential RNA motifs were manually checked for covariance
847 and conservation. For promising candidates, a seed alignment was built and a covariance model
848 search was performed as described above. The transcription start sites for *aca2* operons were
849 predicted using the Salis Lab Promoter Calculator³⁹. Only operons whose protein predictions
850 matched those of Prokka_v (version 1.12-viral)⁵⁵ were regarded as trustworthy and included
851 in **Figure 6C** and **Extended data figure 6B**. We also tested motif identification using a less
852 stringent E-value (0.02), which increased the number of identified motifs. Other manually-
853 curated predictions with higher E-values also resembled those identified bioinformatically and
854 may therefore be widespread in many more (or even all) operons. To enable analyses of
855 statistical high-confidence, we focused on the set identified with an E-value threshold of 0.001.

856

857 **Phylogenetic tree of the Helix-turn-Helix domain of Aca2**

858 In the first step, the operons containing only *Aca2* were removed from the non-redundant
859 operon set because they do not have an RNA motif before their start codon. In a second step,
860 the amino acid sequences of the *Aca2* proteins were extracted from the operons using
861 prokka_v⁵⁵ (version 1.12-viral). The predicted host of each operon was extracted from the
862 IMG/VR database⁵⁶. The amino acid sequences were aligned using T-COFFEE

863 (<https://www.ebi.ac.uk/Tools/msa/tcoffee/>)⁵⁷ The resulting alignment was used as an input file
864 with default parameters for FastTree (version 2.1.11)⁵⁸ and the tree was visualized using the
865 webservice Interactive Tree of Life⁵⁹.

866

867 **Nucleotide-nucleotide and nucleotide-amino acid covariation identification**

868 The R-scape web server (<http://eddylab.org/R-scape/>) was used to analyse nucleotide-
869 nucleotide covariation. The high confidence set of each motif and standard parameters were
870 used as input. The command line R-scape (version 2.0.0) was used to analyse the covariation
871 between nucleotides of the DNA and RNA motifs and helix3 of Aca2. For this analysis, a
872 subset of the RNA and DNA motifs was manually selected based on the similarity of the
873 nucleotide sequences so that the sequences were neither too similar nor dissimilar. This subset
874 was combined with the corresponding amino acid sequence of the HTH recognition helix (helix
875 3), which was extracted and realigned from the Aca2 alignment (see phylogenetic tree) of their
876 respective Aca2 proteins into a Stockholm file. This file was used as the input file for the R-
877 scape command line tool with the default parameters and covariation with the helix 3 sequence
878 was separately tested for the DNA (IR1) and RNA (IR2) motifs of the proteo-motif group.

879

880 **Data availability**

881 The cryo-EM map of the Aca2–RNA complex has been deposited in the Electron Microscopy
882 Data Bank (accession code 43762). Raw cryo-EM micrographs have been deposited to
883 EMPIAR (accession code EMPIAR-11918). The coordinates of the atomic model have been
884 deposited in the Protein Data Bank (accession code 8W35). Code for the mathematical
885 modelling is available at https://github.com/JacksonLab/Modelling_Aca-Acr/ and for
886 bioinformatic analysis of Aca2 family proteins and their associated motifs at
887 <https://gitfront.io/r/MFeussner/HRVEg3nda6kT/Aca2-Bioinformatic/>.

888 **Acknowledgements**

889 This work was supported by a University of Otago Research Grant, the former Bio-Protection
890 Research Centre (Tertiary Education Commission, NZ) and Bioprotection Aotearoa (TEC,
891 NZ). NB and KK were supported by University of Otago Doctoral Scholarships. PCF was
892 supported by an Experienced Researcher Fellowship from the Alexander von Humboldt
893 Foundation and a James Cook Research Fellowship from the Royal Society Te Apārangi of
894 New Zealand. SAJ was supported by the Health Research Council of New Zealand (Sir Charles
895 Hercus Fellowship). MF was supported by a fellowship of the German Academic Exchange
896 Service (DAAD) and by German Research Foundation (DFG) grant 468749960 to ZW. CLB
897 was supported by a European Research Council Consolidator Grant [865973]. MEW was
898 supported by a Helen Hay Whitney Foundation / HHMI postdoctoral fellowship and thanks
899 Feng Zhang for funding support. SCW was supported by an Engineering and Physical Sciences
900 Research Council Molecular Sciences for Medicine Centre for Doctoral Training studentship
901 [grant number EP/S022791/1]. BU was supported by a Springboard Award from the Academy
902 of Medical Sciences [grant number SBF002\1104]. TRB was funded by a Lister Institute Prize
903 Fellowship. We thank Sophia Valabhji and Tom Arrowsmith for assistance with SEC. We
904 gratefully acknowledge use of the Otago Micro and Nanoscale Imaging (OMNI) Flow
905 Cytometry unit. We thank Ed Brignole and Chris Borsa for the smooth running the MIT.nano
906 cryo-EM facility, established in part with financial support from the Arnold and Mabel
907 Beckman Foundation.

908

909 **Author contributions**

910 NB, RDF, SAJ and PCF conceived the study. NB and PCF coordinated the study. All authors
911 designed experiments. NB, KK, MF, MEW, CCS, AM, DK, MC, SCW, BU, RDF and SAJ
912 performed experiments, modelling and bioinformatics, with additional analyses provided by
913 TRB, CMB, CLB, ZW and PCF. NB generated figures, except for structure figures which were
914 created by MEW. NB and PCF wrote the manuscript with input from the other authors. NB,
915 TRB, CMB, CLB, ZW, RDF, SAJ and PCF provided supervision.


916

917 **Competing interest declaration**

918 PCF and RDF are inventors on patent applications related to CRISPR–Cas systems and
919 applications thereof. CLB is a co-founder of Leopard Biosciences, co-founder and member of
920 the Scientific Advisory Board of Locus Biosciences and a member of the Scientific Advisory
921 Board of Benson Hill.

922 **Extended data figures**

923



924

925

926

927

928

929

930

931

932


933

934

935


936

Extended data figure 1: Phage engineering and phage escape mutants. **A)** Illustration of the two-step engineering approach for phage ZF40 using the endogenous type I-E CRISPR–Cas system of its host *P. carotovorum* RC5297. First, the locus to be altered (purple) is deleted using a “deletion plasmid” in which appropriate homologous regions (grey) flank a placeholder. The plasmid also contains a type I-E spacer (red) targeting the original locus, resulting in the selection for phages that have integrated the placeholder. Next, recombinant phages are used to infect cells containing an “addition plasmid” with any locus of choice (yellow) flanked by homology regions; the plasmid also contains a I-E spacer (pink) targeting the placeholder. This results in the selection for and release of phages containing the locus of choice. **B)** Sequences of wild-type and escape mutant phages in the region surrounding IR1, -10 and -35 motifs. Mutants 1 to 3, with their genotypes indicated, were isolated from plaques formed in the absence of the Aca2 helper plasmids. Point mutations in the sequence are indicated in red.




937
938
939
940
941
942
943

Extended data figure 2: Investigation of the *acrIF8-aca2* 5' UTR and its interaction with *Aca2*. **A)** Sequencing trace of cDNA generated from the *P. carotovorum* ZM1 transcriptome using a template-switching reverse transcriptase. The 3' end of the indicated template-switching oligo sequence borders the 5' end of the transcript, thus allowing identification of the transcription start site. **B)** Size-exclusion chromatography traces of *Aca2* alone or *Aca2* incubated with the 37-nt RNA shown on the right.




944
 945
 946
 947
 948
 949
 950
 951

Extended data figure 3: Comparison of the *acrIF8-eyfp* reporter operon with the wild-type *acrIF8-aca2* operon. A) Overview of both operons. In the reporter construct, the red dot indicates a premature stop codon and the downstream *acrIF8* sequence is shown in a lighter shade. Areas in grey boxes are shown in panels B and C. B) Detailed view of the promoter and 5' UTR region of both operons, with regulatory motifs indicated. C) Detailed view of the intergenic region between *acrIF8* and *aca2* (wild-type operon) or *acrIF8* and *eyfp* (reporter construct). Note that in the reporter construct, the first three codons of *aca2* are fused to *eyfp*.



952
953
954
955
956
957
958
959
960
961

Extended data figure 4: Aca2 residues involved in DNA and RNA binding. **A)** Cryo-EM density of the 38-kDa Aca2–RNA complex at 2.6 Å resolution. **B)** Close-up view of residues Arg30 (R30), Tyr34 (Y34) and Arg39 (R39) in the Aca2–RNA complex (interacting with IR2 or IR-RBS) and the Aca2–DNA complex. **C)** Clustal Omega Alignment of Aca2 homologs from the indicated species (with accession numbers indicated on the right) to the first 60 amino acids of Aca2. Residues involved in DNA and RNA binding are highlighted in purple, residues only involved in RNA binding in green. Asterisks indicate conserved residues whereas colons and periods indicate conservation between groups of strongly and weakly similar properties, respectively.



963

964

965

966

967

968

969

970


971

972

973

974

Extended data figure 5: Impact of different regulation modes on AcrIF8 levels and production rate. **A**) Modelled mean *acrIF8-aca2* mRNA levels (solid green line) over a period of 60 min (based on 250 simulations), with the standard deviation indicated by lighter shading. **B-D**) Acr production rates as in **Figure 5B** but for different modes of regulation: only DNA-based transcriptional regulation (**B**), only RNA-based translational regulation (**C**), or no regulation (**D**). The green line in panels **B-D** represents the fully regulated state for comparison (same data as displayed in **Figure 5B**). **E**) Time courses corresponding to the end point data in **Figure 5E** for the indicated modes of regulation and final phage genome copy numbers. **F**) Experimental data for plasmids of different origins and unregulated *eyfp-aca2* operons, with eYFP fluorescence detected by flow cytometry. The determined copy numbers for each plasmid are indicated with a circle.



975
 976
 977
 978
 979
 980
 981
 982
 983
 984
 985
 986
 987
 988
 989
 990
 991

Extended data figure 6: Aca2-encoding operons are associated with predicted 5' UTR RNA motifs. **A)** Phylogenetic tree of a set of 145 Aca2 homologs. Coloured boxes at the ends of the branches indicate the bacterial phylum of origin for the corresponding operon, and coloured dots indicate the presence or absence of proteo- and actino-motifs associated with the operons. **B)** Position plot displaying, relative to the transcription start site, the locations of the DNA binding motif (corresponding to IR1 in the ZF40 *acrIF8-aca2* promoter), the actino-motif for RNA-based regulation and the start codon. Approximate locations of promoter motifs (-10, -35) are indicated on the x axis. **C)** Structure and sequence conservation within the actino-motif and its upstream DNA motif. Coloured boxes represent the presence of any nucleotide at this position, with the frequency indicated by the shade as described on the right; coloured letters indicate the likelihood of the nucleotide identity at this position. **D)** Co-variation analysis of a subset of *aca2*-containing operons for the Aca2 HTH domain (helix $\alpha 3$ shown) and the IR1 and IR2 sequences. Co-varying residues are indicated by vertical purple and yellow bars. Note that the nucleotide complementary to the co-varying nucleotide in IR2 (grey bar) does not significantly co-vary, likely because a T at this position can, as a U at the RNA level, base-pair with either A or G, thus requiring fewer evolutionary changes.

992 **References**

993

- 994 1 Aravind, L., Anantharaman, V., Balaji, S., Babu, M. M. & Iyer, L. M. The many faces of
 995 the helix-turn-helix domain: Transcription regulation and beyond. *FEMS Microbiology*
 996 *Reviews* **29**, 231-262 (2005). <https://doi.org/10.1016/j.femsre.2004.12.008>
- 997 2 Birkholz, N., Fagerlund, R. D., Smith, L. M., Jackson, S. A. & Fineran, P. C. The
 998 autoregulator Aca2 mediates anti-CRISPR repression. *Nucleic Acids Research* **47**,
 999 9658-9665 (2019). <https://doi.org/10.1093/nar/gkz721>
- 1000 3 Stanley, S. Y. *et al.* Anti-CRISPR-Associated Proteins Are Crucial Repressors of Anti-
 1001 CRISPR Transcription. *Cell* **178**, 1452-1464 (2019).
 1002 <https://doi.org/10.1016/j.cell.2019.07.046>
- 1003 4 Shehreen, S., Birkholz, N., Fineran, Peter C. & Brown, Chris M. Widespread
 1004 repression of anti-CRISPR production by anti-CRISPR-associated proteins. *Nucleic*
 1005 *Acids Research* **50**, 8615-8625 (2022). <https://doi.org/10.1093/nar/gkac674>
- 1006 5 Lee, S. Y., Birkholz, N., Fineran, P. C. & Park, H. H. Molecular basis of anti-CRISPR
 1007 operon repression by Aca10. *Nucleic Acids Research* **50**, 8919-8928 (2022).
 1008 <https://doi.org/10.1093/nar/gkac656>
- 1009 6 Jacob, F. & Monod, J. Genetic Regulatory Mechanisms in the Synthesis of Proteins.
 1010 *Journal of Molecular Biology* **3**, 318-356 (1961).
 1011 [https://doi.org/https://doi.org/10.1016/S0022-2836\(61\)80072-7](https://doi.org/https://doi.org/10.1016/S0022-2836(61)80072-7)
- 1012 7 Laughon, A. & Scott, M. P. Sequence of a Drosophila segmentation gene: protein
 1013 structure homology with DNA-binding proteins. *Nature* **310**, 25-31 (1984).
 1014 <https://doi.org/10.1038/310025a0>
- 1015 8 McGinnis, W., Garber, R. L., Wirz, J., Kuroiwa, A. & Gehring, W. J. A homologous
 1016 protein-coding sequence in drosophila homeotic genes and its conservation in other
 1017 metazoans. *Cell* **37**, 403-408 (1984). [https://doi.org/https://doi.org/10.1016/0092-8674\(84\)90370-2](https://doi.org/https://doi.org/10.1016/0092-8674(84)90370-2)
- 1019 9 Bürglin, T. R. & Affolter, M. Homeodomain proteins: an update. *Chromosoma* **125**,
 1020 497-521 (2016). <https://doi.org/10.1007/s00412-015-0543-8>
- 1021 10 Biedenkapp, H., Borgmeyer, U., Sippel, A. E. & Klempnauer, K.-H. Viral myb oncogene
 1022 encodes a sequence-specific DNA-binding activity. *Nature* **335**, 835-837 (1988).
 1023 <https://doi.org/10.1038/335835a0>
- 1024 11 McKay, D. B. & Steitz, T. A. Structure of catabolite gene activator protein at 2.9 Å
 1025 resolution suggests binding to left-handed B-DNA. *Nature* **290**, 744-749 (1981).
 1026 <https://doi.org/10.1038/290744a0>
- 1027 12 Anderson, W. F., Ohlendorf, D. H., Takeda, Y. & Matthews, B. W. Structure of the cro
 1028 repressor from bacteriophage λ and its interaction with DNA. *Nature* **290**, 754-758
 1029 (1981). <https://doi.org/10.1038/290754a0>
- 1030 13 Mayo-Muñoz, D., Pinilla-Redondo, R., Birkholz, N. & Fineran, P. C. A host of armor:
 1031 Prokaryotic immune strategies against mobile genetic elements. *Cell Reports* **42**
 1032 (2023). <https://doi.org/10.1016/j.celrep.2023.112672>
- 1033 14 Bondy-Denomy, J., Pawluk, A., Maxwell, K. L. & Davidson, A. R. Bacteriophage genes
 1034 that inactivate the CRISPR/Cas bacterial immune system. *Nature* **493**, 429-432
 1035 (2013). <https://doi.org/10.1038/nature11723>
- 1036 15 Pawluk, A. *et al.* Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in
 1037 diverse bacterial species. *Nature Microbiology* **1**, 16085 (2016).
 1038 <https://doi.org/10.1038/nmicrobiol.2016.85>
- 1039 16 Usher, B. *et al.* Crystal structure of the anti-CRISPR repressor Aca2. *Journal of*
 1040 *Structural Biology* **213**, 107752 (2021).
 1041 <https://doi.org/https://doi.org/10.1016/j.jsb.2021.107752>
- 1042 17 Lee, S. Y., Kim, G. E. & Park, H. H. Molecular basis of transcriptional repression of
 1043 anti-CRISPR by anti-CRISPR-associated 2. *Acta Crystallographica Section D* **78**, 59-
 1044 68 (2022). <https://doi.org/https://doi.org/10.1107/S2059798321011670>

1045 18 Liu, Y. *et al.* Structural basis for anti-CRISPR repression mediated by bacterial operon
1046 proteins Aca1 and Aca2. *Journal of Biological Chemistry* **297**, 101357 (2021).
1047 <https://doi.org/https://doi.org/10.1016/j.jbc.2021.101357>

1048 19 Meaden, S. *et al.* Phage gene expression and host responses lead to infection-
1049 dependent costs of CRISPR immunity. *The ISME Journal* **15**, 534-544 (2021).
1050 <https://doi.org/10.1038/s41396-020-00794-w>

1051 20 Tovkach, F. I. Study of *Erwinia carotovora* Phage Resistance with the Use of
1052 Temperate Bacteriophage ZF40. *Microbiology* **71**, 72-77 (2002).

1053 21 Zhang, K. *et al.* Inhibition mechanisms of AcrF9, AcrF8, and AcrF6 against type I-F
1054 CRISPR–Cas complex revealed by cryo-EM. *Proceedings of the National Academy of
1055 Sciences* **117**, 7176-7182 (2020). <https://doi.org/10.1073/pnas.1922638117>

1056 22 Chen, Y.-J. *et al.* Characterization of 582 natural and synthetic terminators and
1057 quantification of their design constraints. *Nature Methods* **10**, 659-664 (2013).
1058 <https://doi.org/10.1038/nmeth.2515>

1059 23 Osuna, B. A. *et al.* Critical Anti-CRISPR Locus Repression by a Bi-functional Cas9
1060 Inhibitor. *Cell Host & Microbe* **28**, 23-30 (2020).
1061 <https://doi.org/10.1016/j.chom.2020.04.002>

1062 24 Kimanius, D. *et al.* Data-driven regularisation lowers the size barrier of cryo-EM
1063 structure determination. *bioRxiv*, 2023.2010.2023.563586 (2023).
1064 <https://doi.org/10.1101/2023.10.23.563586>

1065 25 Segall-Shapiro, T. H., Sontag, E. D. & Voigt, C. A. Engineered promoters enable
1066 constant gene expression at any copy number in bacteria. *Nature Biotechnology* **36**,
1067 352-358 (2018). <https://doi.org/10.1038/nbt.4111>

1068 26 Bleris, L. *et al.* Synthetic incoherent feedforward circuits show adaptation to the amount
1069 of their genetic template. *Mol Syst Biol* **7**, 519 (2011).
1070 <https://doi.org/https://doi.org/10.1038/msb.2011.49>

1071 27 Rivera-Pomar, R., Niessing, D., Schmidt-Ott, U., Gehring, W. J. & Jackl , H. RNA
1072 binding and translational suppression by bicoid. *Nature* **379**, 746-749 (1996).
1073 <https://doi.org/10.1038/379746a0>

1074 28 Alfano, C. *et al.* Structural analysis of cooperative RNA binding by the La motif and
1075 central RRM domain of human La protein. *Nature Structural & Molecular Biology* **11**,
1076 323-329 (2004). <https://doi.org/10.1038/nsmb747>

1077 29 Dong, G., Chakshusmathi, G., Wolin, S. L. & Reinisch, K. M. Structure of the La motif:
1078 a winged helix domain mediates RNA binding via a conserved aromatic patch. *The
1079 EMBO Journal* **23**, 1000-1007 (2004). <https://doi.org/10.1038/sj.emboj.7600115>

1080 30 Tan, D., Zhou, M., Kiledjian, M. & Tong, L. The ROQ domain of Roquin recognizes
1081 mRNA constitutive-decay element and double-stranded RNA. *Nature Structural &
1082 Molecular Biology* **21**, 679-685 (2014). <https://doi.org/10.1038/nsmb.2857>

1083 31 Schlundt, A. *et al.* Structural basis for RNA recognition in roquin-mediated post-
1084 transcriptional gene regulation. *Nature Structural & Molecular Biology* **21**, 671-678
1085 (2014). <https://doi.org/10.1038/nsmb.2855>

1086 32 Soler, N., Fourmy, D. & Yoshizawa, S. Structural Insight into a Molecular Switch in
1087 Tandem Winged-helix Motifs from Elongation Factor SelB. *Journal of Molecular
1088 Biology* **370**, 728-741 (2007). <https://doi.org/https://doi.org/10.1016/j.jmb.2007.05.001>

1089 33 Yoshizawa, S. *et al.* Structural basis for mRNA recognition by elongation factor SelB.
1090 *Nature Structural & Molecular Biology* **12**, 198-203 (2005).
1091 <https://doi.org/10.1038/nsmb890>

1092 34 Morrison, J., Anderson, K., Beenken, K., Smeltzer, M. & Dunman, P. The
1093 staphylococcal accessory regulator, SarA, is an RNA-binding protein that modulates
1094 the mRNA turnover properties of late-exponential and stationary phase
1095 *Staphylococcus aureus* cells. *Frontiers in Cellular and Infection Microbiology* **2** (2012).
1096 <https://doi.org/10.3389/fcimb.2012.00026>

1097 35 Chu, L.-C. *et al.* The RNA-bound proteome of MRSA reveals post-transcriptional roles
1098 for helix-turn-helix DNA-binding and Rossmann-fold proteins. *Nature Communications*
1099 **13**, 2883 (2022). <https://doi.org/10.1038/s41467-022-30553-8>

1100 36 Conrad, T. *et al.* Serial interactome capture of the human cell nucleus. *Nature*
1101 *Communications* **7**, 11212 (2016). <https://doi.org/10.1038/ncomms11212>

1102 37 Oksuz, O. *et al.* Transcription factors interact with RNA to regulate genes. *Molecular*
1103 *Cell* **83**, 2449-2463.e2413 (2023).
1104 <https://doi.org/https://doi.org/10.1016/j.molcel.2023.06.012>

1105 38 Madeira, F. *et al.* The EMBL-EBI search and sequence analysis tools APIs in 2019.
1106 *Nucleic Acids Research* **47**, W636-W641 (2019). <https://doi.org/10.1093/nar/gkz189>

1107 39 LaFleur, T. L., Hossain, A. & Salis, H. M. Automated model-predictive design of
1108 synthetic promoters to control transcriptional profiles in bacteria. *Nature*
1109 *Communications* **13**, 5159 (2022). <https://doi.org/10.1038/s41467-022-32829-5>

1110 40 Solovyev, V. & Salamov, A. Automatic annotation of microbial genomes and
1111 metagenomic sequences. In: *Metagenomics and its applications in agriculture,*
1112 *biomedicine and environmental studies.* Nova Science Publishers, 61-78 (2011).

1113 41 Proctor, J. R. & Meyer, I. M. CoFold: An RNA secondary structure prediction method
1114 that takes co-transcriptional folding into account. *Nucleic Acids Research* **41**, e102
1115 (2013). <https://doi.org/10.1093/nar/gkt174>

1116 42 Gruber, A. R., Lorenz, R., Bernhart, S. H., Neuböck, R. & Hofacker, I. L. The Vienna
1117 RNA Websuite. *Nucleic Acids Research* **36**, W70-W74 (2008).
1118 <https://doi.org/10.1093/nar/gkn188>

1119 43 Cai, Y. *et al.* A nucleotidyltransferase toxin inhibits growth of *Mycobacterium*
1120 *tuberculosis* through inactivation of tRNA acceptor stems. *Science Advances* **6**,
1121 eabb6651 (2020). <https://doi.org/doi:10.1126/sciadv.abb6651>

1122 44 Kimanius, D., Dong, L., Sharov, G., Nakane, T. & Scheres, S. H. W. New tools for
1123 automated cryo-EM single-particle analysis in RELION-4.0. *Biochemical Journal* **478**,
1124 4169-4185 (2021). <https://doi.org/10.1042/bcj20210708>

1125 45 Bepler, T. *et al.* Positive-unlabeled convolutional neural networks for particle picking in
1126 cryo-electron micrographs. *Nature methods* **16**, 1153-1160 (2019).
1127 <https://doi.org/10.1038/s41592-019-0575-8>

1128 46 Casañal, A., Lohkamp, B. & Emsley, P. Current developments in Coot for
1129 macromolecular model building of Electron Cryo-microscopy and Crystallographic
1130 Data. *Protein Science* **29**, 1055-1064 (2020).
1131 <https://doi.org/https://doi.org/10.1002/pro.3791>

1132 47 Croll, T. ISOLDE: a physically realistic environment for model building into low-
1133 resolution electron-density maps. *Acta Crystallographica Section D* **74**, 519-530
1134 (2018). <https://doi.org/doi:10.1107/S2059798318002425>

1135 48 Liebschner, D. *et al.* Macromolecular structure determination using X-rays, neutrons
1136 and electrons: recent developments in Phenix. *Acta Crystallographica Section D* **75**,
1137 861-877 (2019). <https://doi.org/doi:10.1107/S2059798319011471>

1138 49 Kubitschek, H. E. & Friske, J. A. Determination of bacterial cell volume with the Coulter
1139 Counter. *Journal of Bacteriology* **168**, 1466-1467 (1986).
1140 <https://doi.org/doi:10.1128/jb.168.3.1466-1467.1986>

1141 50 Gillespie, D. T. Exact stochastic simulation of coupled chemical reactions. *The Journal*
1142 *of Physical Chemistry* **81**, 2340-2361 (1977). <https://doi.org/10.1021/j100540a008>

1143 51 Fu, L., Niu, B., Zhu, Z., Wu, S. & Li, W. CD-HIT: accelerated for clustering the next-
1144 generation sequencing data. *Bioinformatics* **28**, 3150-3152 (2012).
1145 <https://doi.org/10.1093/bioinformatics/bts565>

1146 52 Will, S., Reiche, K., Hofacker, I. L., Stadler, P. F. & Backofen, R. Inferring Noncoding
1147 RNA Families and Classes by Means of Genome-Scale Structure-Based Clustering.
1148 *PLOS Computational Biology* **3**, e65 (2007).
1149 <https://doi.org/10.1371/journal.pcbi.0030065>

1150 53 Nawrocki, E. P. & Eddy, S. R. Infernal 1.1: 100-fold faster RNA homology searches.
1151 *Bioinformatics* **29**, 2933-2935 (2013). <https://doi.org/10.1093/bioinformatics/btt509>

1152 54 Yao, Z., Weinberg, Z. & Ruzzo, W. L. CMfinder—a covariance model based RNA motif
1153 finding algorithm. *Bioinformatics* **22**, 445-452 (2005).
1154 <https://doi.org/10.1093/bioinformatics/btk008>

1155 55 Seemann, T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* **30**, 2068-
1156 2069 (2014). <https://doi.org/10.1093/bioinformatics/btu153>
1157 56 Nordberg, H. *et al.* The genome portal of the Department of Energy Joint Genome
1158 Institute: 2014 updates. *Nucleic Acids Research* **42**, D26-D31 (2014).
1159 <https://doi.org/10.1093/nar/gkt1069>
1160 57 Di Tommaso, P. *et al.* T-Coffee: a web server for the multiple sequence alignment of
1161 protein and RNA sequences using structural information and homology extension.
1162 *Nucleic Acids Research* **39**, W13-W17 (2011). <https://doi.org/10.1093/nar/gkr245>
1163 58 Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree 2 – Approximately Maximum-
1164 Likelihood Trees for Large Alignments. *PLoS One* **5**, e9490 (2010).
1165 <https://doi.org/10.1371/journal.pone.0009490>
1166 59 Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic
1167 tree display and annotation. *Nucleic Acids Research* **49**, W293-W296 (2021).
1168 <https://doi.org/10.1093/nar/gkab301>



Citation on deposit: Birkholz, N., Kamata, K., Feussner, M., Wilkinson, M. E., Cuba Samaniego, C., Migur, A., Kimanius, D., Ceelen, M., Went, S. C., Usher, B., Blower, T. R., Brown, C. M., Beisel, C. L., Weinberg, Z., Fagerlund, R. D., Jackson, S. A., & Fineran, P. C. (2024). Phage anti-CRISPR control

by an RNA- and DNA-binding helix–turn–helix protein. *Nature*, 631(8021), 670-677. <https://doi.org/10.1038/s41586-024-07644-1>

For final citation and metadata, visit Durham Research Online URL:

<https://durham-repository.worktribe.com/output/2601749>

Copyright statement: This accepted manuscript is licensed under the Creative Commons Attribution 4.0 licence.

<https://creativecommons.org/licenses/by/4.0/>